Pemphigus Vulgaris Market

Market Overview:

The 7 major pemphigus vulgaris markets reached a value of US$ 265.3 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 519.4 Million by 2034, exhibiting a growth rate (CAGR) of 6.3% during 2024-2034.

The pemphigus vulgaris market has been comprehensively analyzed in IMARC's new report titled "Pemphigus Vulgaris Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Pemphigus vulgaris is a rare autoimmune disorder that affects the skin and mucous membranes, causing painful blistering and erosions. It can affect in various areas of the body, such as the mouth, throat, nose, genitals, abdomen, etc. The symptoms of the condition typically include the formation of fragile, fluid-filled blisters, leaving open sores that are painful and prone to infection. Various other indications are itching, burning, pain in affected areas, fever, fatigue, weight loss, etc. The ailment is diagnosed through a combination of clinical examination, skin biopsy, and blood tests. The healthcare professionals will typically begin by conducting a physical exam to assess the extent and severity of the blistering and erosions. They may also take a biopsy of the affected skin or mucous membrane to look for characteristic changes in the cells and tissues. Additionally, blood tests may be ordered to detect the presence of antibodies associated with pemphigus vulgaris.

The rising cases of immune system malfunction in which antibodies attack the proteins that hold skin cells together are primarily driving the pemphigus vulgaris market. Additionally, the escalating usage of various medications, such as nonsteroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors, penicillamine, etc., which aid in triggering the onset of the ailment, is also propelling the market growth. Besides this, the widespread adoption of immunosuppressive agents in conjunction with corticosteroids to control the immune system and prevent the formation of new blisters is creating a positive outlook for the market. Moreover, the emerging popularity of plasmapheresis for treating severe cases of disease that do not respond to other treatments is acting as another significant growth-inducing factor. This procedure is used to remove autoantibodies and other immune system components that contribute to the development of the ailment. Furthermore, the rising usage of indirect immunofluorescence for diagnosing the disorder, which involves using fluorescent antibodies to detect the presence of autoantibodies, is also augmenting the market growth. Apart from this, the escalating demand for intravenous immunoglobulin therapy among patients with refractory disease or who are unable to tolerate systemic corticosteroids is expected to drive the pemphigus vulgaris market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the pemphigus vulgaris market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for pemphigus vulgaris and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the pemphigus vulgaris market in any manner.

Recent Developments:

• In December 2023, Argenx SE reported the topline results of the ADDRESS trial, which evaluated efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in people with pemphigus vulgaris. According to the ADDRESS data, the proportion of pemphigus vulgaris patients who achieved the primary endpoint of complete remission on a minimal dosage of steroids (CRmin) was not substantially different between efgartigimod SC and placebo.

Key Highlights:

• The reported incidence of pemphigus vulgaris is between 0.1 and 0.5 per 100,000 people every year.
• Pemphigus vulgaris is more common among Ashkenazi Jews, with the average onset occurring between the ages of 40 and 60.
• Also, within the demographics, persons residing in India, Southeast Europeans, and the Middle Eastern are at the highest risk for pemphigus vulgaris.
• Pemphigus Vulgaris is more frequent in women than men by a ratio of 4:1.
• Pemphigus Vulgaris has a mortality rate of around 5-15%.

Drugs:

Rituximab, also known as Rituxan, is a monoclonal antibody drug used to treat certain autoimmune illnesses, including pemphigus vulgaris. It is administered via gradual intravenous infusion (injection through an IV line). Rituximab is a chimeric monoclonal antibody that targets CD20, a surface antigen found on B lymphocytes. It depletes both normal and pathogenic B lymphocytes, while protecting plasma cells and hematopoietic stem cells that do not express the CD20 surface antigen.

PRN1008, Principia's most advanced therapeutic candidate, is an oral,  small molecule, reversible covalent inhibitor of Bruton's tyrosine kinase (BTK), which is found in the signaling pathways of most forms of white blood cells but not T cells or plasma cells. PRN1008 is built on Principia's unique Tailored Covalency platform, which optimizes the drug's safety and efficacy profile, resulting in extended and reversible activity at the target site and quick elimination from the body.

Ianalumab (VAY736) is an anti-B-cell activating factor (BAFF) receptor completely human monoclonal antibody, designed for direct ADCC-mediated B-cell depletion. This drug is being developed by MorphoSys/Novartis for the treatment of pemphigus vulgaris.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the pemphigus vulgaris market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the pemphigus vulgaris market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current pemphigus vulgaris marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the pemphigus vulgaris market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the pemphigus vulgaris market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the pemphigus vulgaris market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of pemphigus vulgaris across the seven major markets?
• What is the number of prevalent cases (2018-2034) of pemphigus vulgaris by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of pemphigus vulgaris by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with pemphigus vulgaris across the seven major markets?
• What is the size of the pemphigus vulgaris patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of pemphigus vulgaris?
• What will be the growth rate of patients across the seven major markets?
   

Pemphigus Vulgaris: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for pemphigus vulgaris drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the pemphigus vulgaris market?
• What are the key regulatory events related to the pemphigus vulgaris market?
• What is the structure of clinical trial landscape by status related to the pemphigus vulgaris market?
• What is the structure of clinical trial landscape by phase related to the pemphigus vulgaris market?
• What is the structure of clinical trial landscape by route of administration related to the pemphigus vulgaris market?